Tripeptide-29 vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Tripeptide-29Anti-Aging & Longevity
FOXO4-DRI- Summary
- Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- Not applicable (topical)
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- Topical
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 0.01-0.1% in formulation
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- Once or twice daily
- 3 consecutive days per cycle
- Key Benefits
- Stimulates fibroblast collagen synthesis via damage-signal mechanism
- Reduces fine lines and improves skin smoothness
- Supports dermal matrix integrity
- Naturally bioidentical to collagen fragment sequences
- Well-tolerated in all skin types
- Synergistic with copper peptides and retinoids
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Excellent tolerability profile
- No documented significant adverse effects at cosmetic concentrations
- Rare sensitivity reactions in individuals with peptide allergies
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —